Ultrasound AI Market
Description
Ultrasound AI Market Overview
The global ultrasound AI market size was estimated at USD 1.82 billion in 2025 and is projected to reach USD 13.56 billion by 2033, growing at a CAGR of 28.55% from 2026 to 2033. Rising demand for accurate and early disease detection, rapid growth in imaging volumes, and government initiatives and regulatory support are significant factors contributing to market growth.
In addition, growing emphasis on cost-efficiency in healthcare delivery and technological advancements in machine learning, NLP, and computer vision are some other factors fueling market growth further.
The increasing demand for precise early disease detection is driving market growth. The rising global prevalence of cancer, cardiovascular, and neurological disorders underscores the need for advanced imaging to facilitate timely interventions. Moreover, AI-powered analysis is essential for identifying subtle anomalies that are likely to be overlooked during manual review. For instance, according to a meta-analysis of 18 studies published in the AJMC in December 2025, found ultrasound-based AI models diagnose ovarian cancer more accurately than sonographers, with an internal validation sensitivity/specificity of 0.95 and AUC 0.98 of 95% and external validation AUC 0.91 compared to sonographers exhibiting a sensitivity of 0.83 (95% CI, 0.62-0.94), a specificity of 0.84.
In addition, automated measurements and risk assessments enhance diagnostic reliability by reducing inconsistencies among radiologists and supporting personalized therapies. Recent developments, such as Exo’s April 2024 FDA-cleared AI tools for heart failure and lung evaluation on the Exo Iris portable ultrasound, illustrate technological progress. The prioritization of value-based care further accelerates the integration of AI ultrasound solutions across healthcare systems.
Moreover, technological advancements in machine learning, natural language processing, and computer vision fuel the growth of AI in the ultrasound industry. Deep learning algorithms are improving in accuracy, enabling more reliable interpretation of complex imaging modalities. For instance, according to a study published in the Nature Scientific Reports Journal in January 2026, Researchers developed a deep learning model using squeeze-and-excitation capsule networks and convolutional bidirectional LSTM (CBLSTM) for diagnosing gallbladder diseases from ultrasound images. This approach analyzes sequences of frames to detect gallstones, cholecystitis, and other disorders with high accuracy, outperforming traditional manual methods.
Global Ultrasound AI Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global ultrasound AI market report based on component, application/modality, end use, and region:
The global ultrasound AI market size was estimated at USD 1.82 billion in 2025 and is projected to reach USD 13.56 billion by 2033, growing at a CAGR of 28.55% from 2026 to 2033. Rising demand for accurate and early disease detection, rapid growth in imaging volumes, and government initiatives and regulatory support are significant factors contributing to market growth.
In addition, growing emphasis on cost-efficiency in healthcare delivery and technological advancements in machine learning, NLP, and computer vision are some other factors fueling market growth further.
The increasing demand for precise early disease detection is driving market growth. The rising global prevalence of cancer, cardiovascular, and neurological disorders underscores the need for advanced imaging to facilitate timely interventions. Moreover, AI-powered analysis is essential for identifying subtle anomalies that are likely to be overlooked during manual review. For instance, according to a meta-analysis of 18 studies published in the AJMC in December 2025, found ultrasound-based AI models diagnose ovarian cancer more accurately than sonographers, with an internal validation sensitivity/specificity of 0.95 and AUC 0.98 of 95% and external validation AUC 0.91 compared to sonographers exhibiting a sensitivity of 0.83 (95% CI, 0.62-0.94), a specificity of 0.84.
In addition, automated measurements and risk assessments enhance diagnostic reliability by reducing inconsistencies among radiologists and supporting personalized therapies. Recent developments, such as Exo’s April 2024 FDA-cleared AI tools for heart failure and lung evaluation on the Exo Iris portable ultrasound, illustrate technological progress. The prioritization of value-based care further accelerates the integration of AI ultrasound solutions across healthcare systems.
Moreover, technological advancements in machine learning, natural language processing, and computer vision fuel the growth of AI in the ultrasound industry. Deep learning algorithms are improving in accuracy, enabling more reliable interpretation of complex imaging modalities. For instance, according to a study published in the Nature Scientific Reports Journal in January 2026, Researchers developed a deep learning model using squeeze-and-excitation capsule networks and convolutional bidirectional LSTM (CBLSTM) for diagnosing gallbladder diseases from ultrasound images. This approach analyzes sequences of frames to detect gallstones, cholecystitis, and other disorders with high accuracy, outperforming traditional manual methods.
Global Ultrasound AI Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global ultrasound AI market report based on component, application/modality, end use, and region:
- Component Outlook (Revenue, USD Million, 2021 - 2033)
- Hardware/ AI-enabled Devices
- Portable systems
- Cart-based systems
- Handheld ultrasound probes
- Software
- Services
- Application/Modality Outlook (Revenue, USD Million, 2021 - 2033)
- Cardiology / Echocardiography
- Radiology
- Obstetrics & Gynecology
- Urology
- Others
- End Use Outlook (Revenue, USD Million, 2021 - 2033)
- Hospitals
- Diagnostic Imaging Centers
- Ambulatory Surgical/Outpatient Centers
- Others
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Thailand
- Latin America
- Brazil
- Argentina
- MEA
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
100 Pages
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Market Definitions
- 1.2.1. Type Segment
- 1.2.2. Product Segment
- 1.2.3. Mode Segment
- 1.2.4. Drug Segment
- 1.2.5. End-use Segment
- 1.3. Information analysis
- 1.3.1. Market formulation & data visualization
- 1.4. Data validation & publishing
- 1.5. Information Procurement
- 1.5.1. Primary Research
- 1.6. Information or Data Analysis
- 1.7. Market Formulation & Validation
- 1.8. Market Model
- 1.9. Total Market: CAGR Calculation
- 1.10. Objectives
- 1.10.1. Objective 1
- 1.10.2. Objective 2
- Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Snapshot
- 2.3. Competitive Insights Landscape
- Chapter 3. Global Employer and Workplace Drug Testing Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook.
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.1.1. Rising demand for pre-employment testing
- 3.2.1.2. Stringent laws mandating alcohol and drug testing in the workplace
- 3.2.1.3. Rising prevalence of substance use in the workplace
- 3.2.2. Market restraint analysis
- 3.2.2.1. Changing legal environment and changing societal norms
- 3.2.3. Market opportunity analysis
- 3.2.3.1. Technological advancement in drug testing for workplace
- 3.3. Global Employer and Workplace Drug Testing Market Analysis Tools
- 3.3.1. Industry Analysis - Porter’s
- 3.3.2. PESTEL Analysis
- Chapter 4. Global Employer and Workplace Drug Testing Market: Type Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Global Employer and Workplace Drug Testing Market Type Movement Analysis
- 4.3. Global Employer and Workplace Drug Testing Market Size & Trend Analysis, by type, 2021 to 2033 (USD Million)
- 4.4. Pre-employment Drug Screens
- 4.4.1. Pre-employment drug screens market estimates and forecasts 2021 to 2033 (USD Million)
- 4.5. Post-employment
- 4.5.1. Post-employment market estimates and forecasts 2021 to 2033 (USD Million)
- Chapter 5. Global Employer and Workplace Drug Testing Market: Product Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Global Employer and Workplace Drug Testing Market Product Movement Analysis
- 5.3. Global Employer and Workplace Drug Testing Market Size & Trend Analysis, by product, 2021 to 2033 (USD Million)
- 5.4. Consumables
- 5.4.1. Consumables market estimates and forecasts 2021 to 2033 (USD Million)
- 5.5. Instruments
- 5.5.1. Instruments market estimates and forecasts 2021 to 2033 (USD Million)
- 5.6. Rapid Testing Devices
- 5.6.1. Rapid testing devices market estimates and forecasts 2021 to 2033 (USD Million)
- 5.7. Services
- 5.7.1. Services market estimates and forecasts 2021 to 2033 (USD Million)
- Chapter 6. Global Employer and Workplace Drug Testing Market: Mode Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. Global Employer and Workplace Drug Testing Market Mode Movement Analysis
- 6.3. Global Employer and Workplace Drug Testing Market Size & Trend Analysis, by mode, 2021 to 2033 (USD Million)
- 6.4. Urine
- 6.4.1. Urine market estimates and forecasts 2021 to 2033 (USD Million)
- 6.5. Hair
- 6.5.1. Hair market estimates and forecasts 2021 to 2033 (USD Million)
- 6.6. Oral Fluid
- 6.6.1. Oral fluid market estimates and forecasts 2021 to 2033 (USD Million)
- 6.7. Instant testing
- 6.7.1. Instant testing market estimates and forecasts 2021 to 2033 (USD Million)
- Chapter 7. Global Employer and Workplace Drug Testing Market: Drug Estimates & Trend Analysis
- 7.1. Segment Dashboard
- 7.2. Global Employer and Workplace Drug Testing Market Drug Movement Analysis
- 7.2.1. Global Employer and Workplace Drug Testing Market Size & Trend Analysis, by drug, 2021 to 2033 (USD Million)
- 7.3. Alcohol
- 7.3.1. Alcohol market estimates and forecasts 2021 to 2033 (USD Million)
- 7.4. Cannabis/Marijuana
- 7.4.1. Cannabis/marijuana market estimates and forecasts 2021 to 2033 (USD Million)
- 7.5. Cocaine
- 7.5.1. Cocaine market estimates and forecasts 2021 to 2033 (USD Million)
- 7.6. Opioids
- 7.6.1. Opioids testing market estimates and forecasts 2021 to 2033 (USD Million)
- 7.7. Amphetamine & Methamphetamine
- 7.7.1. Amphetamine & methamphetamine market estimates and forecasts 2021 to 2033 (USD Million)
- 7.8. LSD
- 7.8.1. LSD market estimates and forecasts 2021 to 2033 (USD Million)
- 7.9. Others
- 7.9.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
- Chapter 8. Global Employer and Workplace Drug Testing Market: End Use Estimates & Trend Analysis
- 8.1. Segment Dashboard
- 8.2. Global Employer and Workplace Drug Testing Market End Use Movement Analysis
- 8.2.1. Global Employer and Workplace Drug Testing Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
- 8.3. IT/Finance
- 8.3.1. IT/finance market estimates and forecasts 2021 to 2033 (USD Million)
- 8.4. Manufacturing
- 8.4.1. Manufacturing market estimates and forecasts 2021 to 2033 (USD Million)
- 8.5. Transportation
- 8.5.1. Transportation market estimates and forecasts 2021 to 2033 (USD Million)
- 8.6. Construction
- 8.6.1. Construction market estimates and forecasts 2021 to 2033 (USD Million)
- 8.7. Retail and Hospitality
- 8.7.1. Retail and hospitality market estimates and forecasts 2021 to 2033 (USD Million)
- 8.8. Healthcare
- 8.8.1. Healthcare market estimates and forecasts 2021 to 2033 (USD Million)
- 8.9. Education
- 8.9.1. Education surgical centers market estimates and forecasts 2021 to 2033 (USD Million)
- 8.10. Other Professional Services
- 8.10.1. Other Professional Services market estimates and forecasts 2021 to 2033 (USD Million)
- Chapter 9. Employer and Workplace Drug Testing Market: Regional Estimates & Trend Analysis
- 9.1. Regional Dashboard
- 9.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
- 9.3. North America
- 9.3.1. U.S.
- 9.3.1.1. Key country dynamics
- 9.3.1.2. Regulatory framework/ reimbursement structure
- 9.3.1.3. Competitive scenario
- 9.3.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
- 9.3.2. Canada
- 9.3.2.1. Key country dynamics
- 9.3.2.2. Regulatory framework/ reimbursement structure
- 9.3.2.3. Competitive scenario
- 9.3.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
- 9.3.3. Mexico
- 9.3.3.1. Key country dynamics
- 9.3.3.2. Regulatory framework/ reimbursement structure
- 9.3.3.3. Competitive scenario
- 9.3.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
- 9.4. Europe
- 9.4.1. UK
- 9.4.1.1. Key country dynamics
- 9.4.1.2. Regulatory framework/ reimbursement structure
- 9.4.1.3. Competitive scenario
- 9.4.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
- 9.4.2. Germany
- 9.4.2.1. Key country dynamics
- 9.4.2.2. Regulatory framework/ reimbursement structure
- 9.4.2.3. Competitive scenario
- 9.4.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
- 9.4.3. France
- 9.4.3.1. Key country dynamics
- 9.4.3.2. Regulatory framework/ reimbursement structure
- 9.4.3.3. Competitive scenario
- 9.4.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
- 9.4.4. Italy
- 9.4.4.1. Key country dynamics
- 9.4.4.2. Regulatory framework/ reimbursement structure
- 9.4.4.3. Competitive scenario
- 9.4.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
- 9.4.5. Spain
- 9.4.5.1. Key country dynamics
- 9.4.5.2. Regulatory framework/ reimbursement structure
- 9.4.5.3. Competitive scenario
- 9.4.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
- 9.4.6. Norway
- 9.4.6.1. Key country dynamics
- 9.4.6.2. Regulatory framework/ reimbursement structure
- 9.4.6.3. Competitive scenario
- 9.4.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
- 9.4.7. Sweden
- 9.4.7.1. Key country dynamics
- 9.4.7.2. Regulatory framework/ reimbursement structure
- 9.4.7.3. Competitive scenario
- 9.4.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
- 9.4.8. Denmark
- 9.4.8.1. Key country dynamics
- 9.4.8.2. Regulatory framework/ reimbursement structure
- 9.4.8.3. Competitive scenario
- 9.4.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
- 9.5. Asia Pacific
- 9.5.1. Japan
- 9.5.1.1. Key country dynamics
- 9.5.1.2. Regulatory framework/ reimbursement structure
- 9.5.1.3. Competitive scenario
- 9.5.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
- 9.5.2. China
- 9.5.2.1. Key country dynamics
- 9.5.2.2. Regulatory framework/ reimbursement structure
- 9.5.2.3. Competitive scenario
- 9.5.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
- 9.5.3. India
- 9.5.3.1. Key country dynamics
- 9.5.3.2. Regulatory framework/ reimbursement structure
- 9.5.3.3. Competitive scenario
- 9.5.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
- 9.5.4. Australia
- 9.5.4.1. Key country dynamics
- 9.5.4.2. Regulatory framework/ reimbursement structure
- 9.5.4.3. Competitive scenario
- 9.5.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
- 9.5.5. South Korea
- 9.5.5.1. Key country dynamics
- 9.5.5.2. Regulatory framework/ reimbursement structure
- 9.5.5.3. Competitive scenario
- 9.5.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
- 9.5.6. Thailand
- 9.5.6.1. Key country dynamics
- 9.5.6.2. Regulatory framework/ reimbursement structure
- 9.5.6.3. Competitive scenario
- 9.5.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
- 9.6. Latin America
- 9.6.1. Brazil
- 9.6.1.1. Key country dynamics
- 9.6.1.2. Regulatory framework/ reimbursement structure
- 9.6.1.3. Competitive scenario
- 9.6.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
- 9.6.2. Argentina
- 9.6.2.1. Key country dynamics
- 9.6.2.2. Regulatory framework/ reimbursement structure
- 9.6.2.3. Competitive scenario
- 9.6.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
- 9.7. MEA
- 9.7.1. South Africa
- 9.7.1.1. Key country dynamics
- 9.7.1.2. Regulatory framework/ reimbursement structure
- 9.7.1.3. Competitive scenario
- 9.7.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
- 9.7.2. Saudi Arabia
- 9.7.2.1. Key country dynamics
- 9.7.2.2. Regulatory framework/ reimbursement structure
- 9.7.2.3. Competitive scenario
- 9.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
- 9.7.3. UAE
- 9.7.3.1. Key country dynamics
- 9.7.3.2. Regulatory framework/ reimbursement structure
- 9.7.3.3. Competitive scenario
- 9.7.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
- 9.7.4. Kuwait
- 9.7.4.1. Key country dynamics
- 9.7.4.2. Regulatory framework/ reimbursement structure
- 9.7.4.3. Competitive scenario
- 9.7.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)
- Chapter 10. Competitive Landscape
- 10.1. Company/Competition Categorization
- 10.2. Strategy Mapping
- 10.3. Company Market Share Analysis, 2025
- 10.4. List of Key Certification Providers/Scheme Owners
- 10.5. Company Profiles/Listing
- 10.5.1. First Advantage
- 10.5.1.1. Company overview
- 10.5.1.2. Financial performance
- 10.5.1.3. Product benchmarking
- 10.5.1.4. Strategic initiatives
- 10.5.2. Laboratory Corporation of America Holdings (Labcorp)
- 10.5.2.1. Company overview
- 10.5.2.2. Financial performance
- 10.5.2.3. Product benchmarking
- 10.5.2.4. Strategic initiatives
- 10.5.3. Drägerwerk AG & Co. KGaA
- 10.5.3.1. Company overview
- 10.5.3.2. Financial performance
- 10.5.3.3. Product benchmarking
- 10.5.3.4. Strategic initiatives
- 10.5.4. Bio-Rad Laboratories, Inc.
- 10.5.4.1. Company overview
- 10.5.4.2. Financial performance
- 10.5.4.3. Product benchmarking
- 10.5.4.4. Strategic initiatives
- 10.5.5. Abbott
- 10.5.5.1. Company overview
- 10.5.5.2. Financial performance
- 10.5.5.3. Product benchmarking
- 10.5.5.4. Strategic initiatives
- 10.5.6. Clinical Reference Laboratory Inc.
- 10.5.6.1. Company overview
- 10.5.6.2. Financial performance
- 10.5.6.3. Product benchmarking
- 10.5.6.4. Strategic initiatives
- 10.5.7. Quest Diagnostics
- 10.5.7.1. Company overview
- 10.5.7.2. Financial performance
- 10.5.7.3. Product benchmarking
- 10.5.7.4. Strategic initiatives
- 10.5.8. Cordant Health Solutions
- 10.5.8.1. Company overview
- 10.5.8.2. Financial performance
- 10.5.8.3. Product benchmarking
- 10.5.8.4. Strategic initiatives
- 10.5.9. DISA Global Solutions
- 10.5.9.1. Company overview
- 10.5.9.2. Financial performance
- 10.5.9.3. Product benchmarking
- 10.5.9.4. Strategic initiatives
- 10.5.10. HireRight, LLC
- 10.5.10.1. Company overview
- 10.5.10.2. Financial performance
- 10.5.10.3. Product benchmarking
- 10.5.10.4. Strategic initiatives
- 10.5.11. OraSure Technologies, Inc.
- 10.5.11.1. Company overview
- 10.5.11.2. Financial performance
- 10.5.11.3. Product benchmarking
- 10.5.11.4. Strategic initiatives
- 10.5.12. Psychemedics Corporation
- 10.5.12.1. Company overview
- 10.5.12.2. Financial performance
- 10.5.12.3. Product benchmarking
- 10.5.12.4. Strategic initiatives
- 10.5.13. Omega Laboratories
- 10.5.13.1. Company overview
- 10.5.13.2. Financial performance
- 10.5.13.3. Product benchmarking
- 10.5.13.4. Strategic initiatives
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
